Interventional × Precursor Cell Lymphoblastic Leukemia-Lymphoma × tanespimycin × Clear all
NCT00096005 2014-02-24

Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
NCT00098423 2013-09-30

Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Completed
42 enrolled
NCT00004065 2013-06-24

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
NCT00103272 2013-06-04

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

National Cancer Institute (NCI)

Phase 1 Terminated
74 enrolled
NCT00354185 2013-05-16

PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
NCT00004241 2013-02-07

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma

National Cancer Institute (NCI)

Phase 1 Completed
60 enrolled
NCT00132015 2012-03-15

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
37 enrolled
NCT00004075 2011-08-03

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

Mayo Clinic

Phase 1 Completed